Lineage Cell Therapeutics (LCTX) EV to CFO (2022)
Lineage Cell Therapeutics' EV to CFO was 131.95 in Q4 2022, up 270.6% from the prior quarter.
Analysis
Lineage Cell Therapeutics (LCTX) EV to CFO (2022) Analysis & Trends
From Q1 2022 onward, Lineage Cell Therapeutics has reported EV to CFO for 4 quarters.
- Per Business Quant data, LCTX's EV to CFO in the three quarters before Q4 2022 was 35.60 (Q3 2022), 47.28 (Q2 2022) and 31.23 (Q1 2022).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn |
| 10 | Lineage Cell Therapeutics | 245.32 Mn | 43.73 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 131.95 |
| Sep 30, 2022 | 35.60 |
| Jun 30, 2022 | 47.28 |
| Mar 31, 2022 | 31.23 |
API Access
Lineage Cell Therapeutics EV to CFO API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=LCTX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-cfo", "ticker": "LCTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=LCTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();